At CVS Health®, we are committed to making healthcare more accessible and affordable for everyone. One way we do this is by promoting the use of high-quality, cost-effective medications, including biosimilar drugs. Biosimilars are a game changer in the healthcare industry, providing an essential solution for patients who require treatment for chronic and severe conditions.
In a recent report written by Dr. Sree Chaguturu, Executive Vice President and Chief Medical Officer at CVS Health, the benefits of biosimilar drugs are highlighted. The report discusses how these medications can be used to treat a wide range of conditions, from certain types of cancer to diabetes, and how they represent a significant opportunity for managing drug costs within the healthcare system.
Cordavis™, a CVS Health subsidiary that focuses on producing high-quality biosimilars, plays a crucial role in improving patient access to these life-changing treatments and driving innovation in healthcare. By investing in cutting-edge technology and expertise, Cordavis™ is able to produce biosimilars that are just as effective as their branded counterparts but at a fraction of the cost.
To learn more about the impact of biosimilar drugs and how they are making healthcare more accessible, you can read the full report (PDF) authored by Dr. Sree Chaguturu.